In a report released today, James Orsborne from Stifel Nicolaus maintained a Buy rating on Oxford BioMedica (OXBDF – Research Report), with a price target of p500.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
James Orsborne has given his Buy rating due to a combination of factors that highlight Oxford BioMedica’s promising financial trajectory. The company is on course to achieve EBITDA profitability by 2025, supported by a robust order book that showed a significant year-over-year increase, indicating strong future revenue streams. The trading update revealed that Oxford BioMedica is aligned with its revenue guidance, showing impressive growth rates that attest to its operational strength.
Despite some macroeconomic challenges and a tight funding environment, Oxford BioMedica’s current valuation appears attractive, with its EV/sales expected to decrease significantly by 2027. This valuation, coupled with the company’s strong growth momentum in the cell and gene therapy space, suggests potential for further stock price appreciation, making it a compelling investment opportunity.